NCT01916174View on ClinicalTrials.gov

A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
DiabetesDiabetes Mellitus, Type 2Healthy
Interventions
DRUG

insulin degludec/liraglutide

Subject will receive a single injection (s.c.) of IDegLira B5

DRUG

insulin degludec/liraglutide

Subject will receive a single injection (s.c.) of IDegLira V2

Trial Locations (1)

41460

Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY